PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-09-12

Last Posted Date: 2018-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03280173

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Palbociclib in Real World Practice

Completed

Conditions: Advanced Breast Cancer
Metastatic Breast Cancer

Interventions: Other: non-interventional

First Posted Date: 2017-09-12

Last Posted Date: 2023-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 1285

Registration Number: NCT03280303

Locations: 🇺🇸
John Muir Clinical Research Center, Concord, California, United States
🇺🇸
Baptist Health Miami Cancer Institute, Plantation, Florida, United States
🇺🇸
Western Connecticut Health Network, Norwalk, Connecticut, United States

and more 206 locations

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Phase 1

Terminated

Conditions: Healthy
Primary Immune Thrombocytopenia
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions: Drug: PF-06755347 intravenous healthy participant
Drug: Placebo intravenous healthy participant
Drug: PF-06755347 subcutaneous healthy participant
Drug: Placebo subcutaneous healthy participant
Drug: PF-06755347 subcutaneous ITP

First Posted Date: 2017-09-08

Last Posted Date: 2024-07-05

Lead Sponsor: Pfizer

Target Recruit Count: 58

Registration Number: NCT03275740

Locations: 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

and more 3 locations

Immunization To Prevent Acute COPD Exacerbations

Terminated

Conditions: Pneumococcal Infections
COPD

First Posted Date: 2017-09-08

Last Posted Date: 2024-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 530

Registration Number: NCT03276754

Locations: 🇪🇸
Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
🇪🇸
Hospital el Bierzo, Ponferrada, León, Spain
🇪🇸
Hospital Gregorio Marañon, Madrid, Spain

and more 8 locations

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: US-approved Neulasta
Biological: PF-06881894

First Posted Date: 2017-09-06

Last Posted Date: 2018-09-05

Lead Sponsor: Pfizer

Target Recruit Count: 422

Registration Number: NCT03273842

Locations: 🇺🇸
Seaview A Quotient Clinical Business, Miami, Florida, United States
🇺🇸
Quotient Sciences- Jacksonville, LLC, Jacksonville, Florida, United States
🇺🇸
Vince & Associates Clinical Research Inc., Overland Park, Kansas, United States

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: PF-06687234

First Posted Date: 2017-09-01

Last Posted Date: 2021-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03269695

Locations: 🇷🇸
Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇮🇹
ASST Rhodense - Ospedale di Circolo di Rho, Rho, Milano, Italy

and more 30 locations

Glasdegib Absolute Bioavailability Study

Phase 1

Completed

Conditions: Healthy Volunteer Study

Interventions: Drug: Glasdegib Oral Tablet
Drug: Glasdegib IV infusion

First Posted Date: 2017-09-01

Last Posted Date: 2017-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03270878

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2

Completed

Conditions: MSS
RAS-mutant Colorectal Cancer

Interventions: Drug: binimetinib
Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2017-09-01

Last Posted Date: 2022-01-04

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT03271047

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center - South County, Saint Louis, Missouri, United States
🇪🇸
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain

and more 46 locations

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: PF-06863135 + pomalidomide
Drug: PF-06863135 monotherapy IV or SC
Drug: PF-06863135 + dexamethasone
Drug: PF-06863135 + lenalidomide

First Posted Date: 2017-08-31

Last Posted Date: 2024-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT03269136

Locations: 🇺🇸
UC San Diego Medical Center - Hillcrest, San Diego, California, United States
🇺🇸
UChicago Medicine - River East, Chicago, Illinois, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

and more 35 locations

Open Label Safety Study in Acute Treatment of Migraine

Phase 2

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Rimegepant

First Posted Date: 2017-08-30

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 3019

Registration Number: NCT03266588

Locations: 🇺🇸
FutureSearch Trials of Neurology, LP, Dallas, Texas, United States
🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸
Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States

and more 82 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy